attention%20deficit_hyperactivity%20disorder
ATTENTION DEFICIT/HYPERACTIVITY DISORDER
Attention Deficit/Hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization &/or hyperactivity-impulsivity.
Symptoms that suggest ADHD includes hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing task.

Principles of Therapy

  • Inform the parents on the initial titration process and the usual duration of the process
  • Medications should be titrated to maximum doses that control the symptoms with minimum or no adverse effects
  • Prior to starting pharmacotherapy in adolescents, it is important to assess them for symptoms of substance abuse
  • Treatment failure may be a sign of incorrect or incomplete diagnosis. It is recommended to repeat diagnostic evaluation
    • Check for adherence to treatment plan
Consider the following when choosing a medication:
  • Presence of comorbid conditions
    • Treatment of attention-deficit/hyperactivity disorder may sometimes resolve the coexisting condition; however, there are also cases that comorbid conditions should be treated in addition to attention-deficit/hyperactivity disorder management
    • Patients with known structural heart problems should be seen by a cardiologist before being given stimulants and/or Atomoxetine
  • Preferences of the child and/or his or her parent or guardian
  • Potential issues regarding adherence to medication regimen
  • Adverse effects of drugs
  • Potential for drug diversion (where the drug is forwarded on to others for non-prescription uses)
  • Cost of medication

Pharmacotherapy

Stimulant Medications
  • Considered 1st-line therapy
    • Should be combined with behavioral training
  • Only preschool-aged patients who have moderate-severe attention deficit/hyperactivity disorder are considered for pharmacotherapy
    • Methylphenidate may be used if behavior interventions do not provide significant improvement
    • There is moderate evidence to support the efficacy and safety of Methylphenidate in this age group
  • For patients 6-11 years of age, stimulants and/or behavioral training is recommended
  • Although Dextroamphetamine is the only drug approved by United States Food and Drug Administration for patients <6 years of age, there is insufficient evidence to support its safety and efficacy in this age group; hence, it is not recommended by American Academy of Pediatrics (AAP) at this time
  • Lisdexamfetamine is a prodrug of Dextroamphetamine
    • Therapeutically inactive until metabolized in the body
  • Predominantly attributed to binding with the dopamine transporter and subsequent inhibition of dopamine reuptake resulting in increased levels of extracellular dopamine
  • Studies have documented the efficacy of reducing the core symptoms of attention deficit/hyperactivity disorder (hyperactivity, inattention and impulsivity)
    • Also improve the child’s ability to follow rules, decrease over-reactivity of emotions and eventually lead to improved relationships
    • Most patients though improved do not show fully normal behavior
  • Most controlled studies have been based on short-term use
    • Efficacy has been proven at least up to 14 months of use
  • Careful and systematic dosing titration should be done to determine the optimal dosing for an individual
    • Titration can be done on a 3- to 7-day basis
  • All types and dosage forms have been shown to have equal efficacy
  • Individual patient may respond to one type/form but not to another
  • Consider another stimulant if one stimulant does not achieve desired results
  • Consider alternative agents when ≥2 stimulants have been tried without success
    • Specialist referral may be needed
  • Any history or physical examination changes during treatment should warrant consultation to a cardiologist
Alternative Agents
  • Clinicians should seek specialist referral if unfamiliar with use of the following agents
  • Atomoxetine, extended-release Guanfacine and extended-release Clonidine are administered instead of stimulants if there is an issue on possible abuse or diversion of the drug, and if preferred by parents
  • Extended-release Guanfacine and extended-release Clonidine may be given as an adjunctive therapy in patients who partially respond to stimulants
Atomoxetine
  • A United States Food and Drug Administration-approved nonstimulant agent for use in attention deficit/hyperactivity disorder
  • Not yet approved for use in preschool-aged patients
  • Not recommended by the United States Food and Drug Administration in patients with serious heart problems
  • Has shown to be more effective than placebo, in short and longer term (at least 2 years)
    • May be as effective as stimulant medications but more studies are needed
    • Have demonstrated efficacy in reducing core symptoms
  • Long-term safety is yet to be determined
Clonidine
  • May be used in patients 6-11 years of age, either alone or combined with behavioral training
  • Not yet approved for use in preschool-aged patients
  • Have been shown to reduce core symptoms
  • May be more effective for extensive impulsivity/aggression or for tics
    • May take 6-8 weeks to see effect
Guanfacine
  • Have demonstrated efficacy in reducing core symptoms
  • Less sedating than Clonidine and may be an alternative for children with tics
    • May take 6-8 weeks to see effect
  • Not yet approved for use in preschool-aged patients
Tricyclic Antidepressants
  • Only Desipramine and Imipramine have been studied extensively; others include Amitriptyline, Nortriptyline and Clomipramine
  • May only be administered when patients have not responded to licensed drugs for attention deficit/hyperactivity disorder
  • Have larger potential effect on behavior compared to attention or concentration deficits
    • Narrower margin of safety than stimulants
    • More potential adverse reactions than stimulants

Non-Pharmacological Therapy

Develop Management Plan

  • Specific target outcomes should be defined to guide management
    • Primary goal is to maximize function
    • Examples of target outcome include: Improvements in relationships, decrease in disruptive behaviors, improve academic performance, etc
  • Goals should be reviewed with all involved eg parent, patient, school
Behavioral Training
  • Parent and/or teacher-administered behavioral training is the 1st-line treatment in preschool-aged children (ie 4-5 years of age)
  • In patients 6-11 years of age, behavioral training  may be used in combination with stimulants, Atomoxetine, Guanfacine and Clonidine
  • In patients 12-18 years of age, behavioral training  may be suggested as part of pharmacotherapy
  • Provide management strategies to modify the physical and social environment to help modify behavior
  • Cognitive behavioral training - problem-solving strategies that help patients stop and think before acting; used to treat impulsive patients with non-self controlled behavior and problem solving deficits
  • Train parents/caregivers and teachers with specific techniques for improving behavior
    • Positive reinforcement
    • Time-out
    • Response cost
    • Token economy
  • Group-based behavioral interventions are focused on peer relationships or interactions
  • Evidence of effectiveness of behavioral training comes from varied studies
    • Long-term positive effects of behavioral training is still to be determined
    • The large variety in behavioral therapy and outcome measures make meta-analysis difficult
    • Majority of studies comparing behavioral training alone vs stimulant medications show stimulants to be more effective
    • Based on a study, combining behavioral training with medication showed no more efficacy in reducing core symptoms than medication alone
    • Combination therapy also allowed the use of lower drug dosages; hence, reducing the risk of adverse effects
    • Most patients, though improved, do not show fully normal behavior
    • For families who refuse medication therapy, behavioral training  alone has been found to be more effective than no treatment
Social Skills Training
  • Used to teach children practical interpersonal skills in a safe setting
  • Skills taught include maintaining eye contact, strategies for initiating and maintaining conversations, remembering to share and cooperate
Psychological Interventions
  • Different from behavioral interventions
  • Directed at child
    • Psychological interventions are designed to change child’s emotional status or thought patterns
    • Effects: Documented efficacy of psychological treatment of children is lacking
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Sep 2013

New Zealanders are some of the most anxious people in the world, second only to Americans, according to Te Rau Hinengaro – the New Zealand Mental Health Survey (2006; Wellington: the Ministry of Health).

Christina Lau, 20 May 2015
Vertigo is easy to diagnose and treat, with successful treatment possible in more than 90 percent of cases, says an expert at the 20th Hong Kong Medical Forum.
01 Sep 2013

Many insomnia and anxiety sufferers go to the pharmacy for natural health supplements as first-line treatment before seeing a GP, say pharmacy staff, as Pharmacy Today New Zealand reports